Friends of Cancer Research 2018 Impact Report
ADVANCING INNOVATION FOR PATIENTS

Modernizing Clinical Trials

Friends work expands access to new clinical trials for thousands of patients

- Broadening eligibility criteria to make clinical trials more representative

The Future of FDA Innovations

Friends continues to help shape the future of one of the most vital agencies

- Augmenting randomized confirmatory trials for breakthrough therapies with historical clinical trials data
- NCI adopts *Friends-ASCO* recommendations and revises clinical trial protocol template to broaden eligibility criteria
- Measuring tolerability in cancer clinical trials
- White paper: broadening the definition of tolerability in cancer clinical trials

### Precision Medicine and Diagnostics

**Driving innovation for personalized treatment**

- 7th Annual *Friends-Alexandria Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine*
- Developing policies for next-generation diagnostic tests
- Diagnostics: advancing opportunities for innovation, while maximizing protections for patients
- Phase 1 results of *Friends*’ TMR project released at international conference

### Better Treatments for Patients

**Creating methods for cutting-edge science in the real world**

- *Friends* research study seeks to enhance information about prescription drugs
- *Friends* works with Senate to introduce MODERN labeling bill
- *Friends* leads new collaboration to improve use of health data
- A way to evaluate real-world endpoints
- Educating the next-generation of patient advocates
Honoring Anthony Fauci & Richard Klausner

In 2018, Friends honored two extraordinary people at the Cancer Leadership Awards that have contributed greatly to science and cancer research in their own, unique ways: Dr. Richard Klausner and Dr. Anthony Fauci. To learn more about this event, click here.

Friends Presents Unique Approaches to Innovating Drug Development

Friends is proud to host our Annual Meeting to address critical issues in the development of new oncology drugs. To learn more about the 2018 Annual Meeting, click here.

What's Ahead for Biopharma in the New Congress

Featured speakers at this year's BioPharma Congress included HHS Deputy Secretary Eric Hargan and CMS Administrator Seema Verma. The event brought together regulators, industry, patient advocacy groups, and congressional staff as well as payment and reimbursement organizations. To learn more about this event, click here.

On behalf of Friends of Cancer Research, I would like to thank you:

Our Board of Directors, supporters, and collaborators without whom our work would not be possible. In the past year alone, we have made great advances in achieving our mission to help patients and accelerate the development of new treatments. Throughout the year, our projects are designed to catalyze innovative research, policy, and partnerships.

We are proud to share with you the highlights of 2018 and the strides we continue to make on behalf of patients and their loved ones.